The condition, which most often affects people in warm, humid climates where fungal spores are common, can trigger nasal ...

Inflammatory bowel disease (IBD) is a crowded drug market with plenty of treatment options across the two forms of the ...

Eli Lilly expanded its AI drug discovery pact with XtalPi to antibodies. Celltrion in-licensed two innovative autoimmune ...

After spending much of the year sloping steadily downward from a January peak, TV drug ad spending picked up in a major way ...

Akeso has data showing ivonescimab can extend the lives of patients with previously treated EGFR-mutated non-small cell lung ...

Incyte has expanded its support for projects tackling unmet needs to cover hidradenitis suppurativa (HS) patients, tightening ...

Even with Inflation Reduction Act (IRA)-related pressure looming for its top product, Teva Pharmaceuticals is continuing to ...

Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to ...

Less than three months into his tenure, Novo Nordisk’s new CEO has undeniably left his mark on the company, launching a ...

As the prospect of import tariffs and drug price reform marshals billions of biopharma investment dollars into the U.S., the ...

A proposed buyout of Bavarian Nordic by a private equity consortium didn’t win over enough shareholder support, laying to ...

In just its fifth full quarter on the market, the world’s first treatment for metabolic dysfunction-associated ...